TG and metabolic dysfunction-associated steatotic liver disease: As the current therapeutic drugs for NAFLD treatment primarily involve non-specific agents and some clinical trials have observed the beneficial role of thyroid hormone analogs [49] in reducing NAFLD-related steatosis, understanding this role of HT in NAFLD could lead to a clinical breakthrough in NAFLD management.